123 related articles for article (PubMed ID: 6962779)
21. Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients.
Bastholt L; Dalmark M
Cancer Treat Rep; 1987 May; 71(5):451-4. PubMed ID: 3471329
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of oral 4-demethoxydaunorubicin in patients with non-small cell lung cancer.
Kris MG; Gralla RJ; Kelsen DP; Casper ES; Burke MT; Fiore JJ; Cibas IR; Heelan RT
Am J Clin Oncol; 1985 Oct; 8(5):377-9. PubMed ID: 3864366
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of triglycidylurazol given on a 5-day i.v. schedule.
Nicaise C; Rozencweig M; Crespeigne N; Dodion P; Gerard B; Lambert M; Decoster G; Kenis Y
Cancer Treat Rep; 1986 May; 70(5):599-603. PubMed ID: 3708609
[TBL] [Abstract][Full Text] [Related]
24. Phase II trial with oral idarubicin in advanced breast cancer.
Lopez M; Di Lauro L; Papaldo P; Lazzaro B; Ganzina F; Di Pietro N
Invest New Drugs; 1986; 4(1):39-42. PubMed ID: 3457780
[TBL] [Abstract][Full Text] [Related]
25. Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia.
Daghestani AN; Arlin ZA; Leyland-Jones B; Gee TS; Kempin SJ; Mertelsmann R; Budman D; Schulman P; Baratz R; Williams L
Cancer Res; 1985 Mar; 45(3):1408-12. PubMed ID: 3855696
[TBL] [Abstract][Full Text] [Related]
26. Combination chemotherapy with 5-fluorouracil, oral Idarubicin, and cyclophosphamide (FIC) in metastatic breast cancer--an open phase II study.
Kolarić K; Potrebica V; Vukas D; Mechl Z; Sopkova B
J Cancer Res Clin Oncol; 1988; 114(3):301-5. PubMed ID: 3164312
[TBL] [Abstract][Full Text] [Related]
27. A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer.
Smith DB; Howell A
Eur J Cancer Clin Oncol; 1987 Apr; 23(4):391-4. PubMed ID: 3475204
[TBL] [Abstract][Full Text] [Related]
28. Phase II study of idarubicin in advanced cervical carcinoma.
Hakes TB; Dougherty JB; Raymond V
Am J Clin Oncol; 1986 Jun; 9(3):262-3. PubMed ID: 3460321
[TBL] [Abstract][Full Text] [Related]
29. The new anthracycline 4-demethoxydaunorubicin by oral route in advanced pretreated breast cancer and melanoma. A pilot study.
Martoni A; Pacciarini MA; Pannuti F
Drugs Exp Clin Res; 1985; 11(2):127-31. PubMed ID: 3915281
[TBL] [Abstract][Full Text] [Related]
30. Phase I trial of pentamethylmelamine in patients with previously treated malignancies.
Van Echo DA; Chiuten DF; Whitacre M; Aisner J; Lichtenfeld JL; Wiernik PH
Cancer Treat Rep; 1980; 64(12):1335-9. PubMed ID: 6781747
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of idarubicin administered orally on a daily x 3 schedule.
Stewart DJ; Verma S; Maroun JA; Robillard L; Perrault DJ; Young V; Gupta S; Fontaine B
Invest New Drugs; 1990 Aug; 8(3):275-81. PubMed ID: 2272768
[TBL] [Abstract][Full Text] [Related]
32. A phase I trial of marcellomycin with a weekly dose schedule.
Joss RA; Kaplan S; Goldhirsch A; Varini M; Brunner KW; Cavalli F
Eur J Cancer Clin Oncol; 1983 Apr; 19(4):455-9. PubMed ID: 6683183
[TBL] [Abstract][Full Text] [Related]
33. Phase I trial of menogaril administered as an intermittent daily infusion for 5 days.
Sigman LM; Van Echo DA; Egorin MJ; Whitacre MY; Aisner J
Cancer Treat Rep; 1986 Jun; 70(6):721-5. PubMed ID: 2942244
[TBL] [Abstract][Full Text] [Related]
34. Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
Toffoli G; Sorio R; Aita P; Crivellari D; Corona G; Bearz A; Robieux I; Colussi AM; Stocco F; Boiocchi M
Clin Cancer Res; 2000 Jun; 6(6):2279-87. PubMed ID: 10873078
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.
Gillies HC; Herriott D; Liang R; Ohashi K; Rogers HJ; Harper PG
Br J Clin Pharmacol; 1987 Mar; 23(3):303-10. PubMed ID: 3471265
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
Judson IR; Calvert AH; Rutty CJ; Abel G; Gumbrell LA; Graham MA; Evans BD; Wilman DE; Ashley SE; Cairnduff F
Cancer Res; 1989 Oct; 49(19):5475-9. PubMed ID: 2670205
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule.
Von Hoff DD; Howser K; Gormley P; Bender RA; Glaubiger D; Levine AS; Young RC
Cancer Treat Rep; 1978 Oct; 62(10):1421-6. PubMed ID: 361222
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma.
Chisesi T; Capnist G; de Dominicis E; Dini E
Eur J Cancer Clin Oncol; 1988 Apr; 24(4):681-4. PubMed ID: 3164269
[TBL] [Abstract][Full Text] [Related]
39. Oral 4-demethoxydaunorubicin (idarubicin) in bronchogenic lung cancer; phase II trial.
Hochster HS; Green MD; Blum RH; Wernz JC; Speyer JL; Muggia FM
Invest New Drugs; 1986; 4(3):275-8. PubMed ID: 3469171
[TBL] [Abstract][Full Text] [Related]
40. Fluorescence assay of tissue distribution of 4-demethoxydaunorubicin and 4-demethoxydoxorubicin in mice bearing solid tumors.
Formelli F; Casazza AM; Di Marco A; Mariani A; Pollini C
Cancer Chemother Pharmacol; 1979; 3(4):261-9. PubMed ID: 294954
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]